Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Catherine Crowe is active.

Publication


Featured researches published by Catherine Crowe.


European Journal of Endocrinology | 2013

ATLANTIC DIP: simplifying the follow-up of women with previous gestational diabetes

E. Noctor; Catherine Crowe; Louise Carmody; G M Avalos; Breda Kirwan; Jennifer J. Infanti; Angela O'Dea; Paddy Gillespie; John Newell; Brian E. McGuire; Ciaran O'Neill; P M O'Shea; Fidelma Dunne

OBJECTIVE Previous gestational diabetes (GDM) is associated with a significant lifetime risk of type 2 diabetes. In this study, we assessed the performance of HbA1c and fasting plasma glucose (FPG) measurements against that of 75 g oral glucose tolerance testing (OGTT) for the follow-up screening of women with previous GDM. METHODS Two hundred and sixty-six women with previous GDM underwent the follow-up testing (mean of 2.6 years (s.d. 1.0) post-index pregnancy) using HbA1c (100%), and 75 g OGTT (89%) or FPG (11%). American Diabetes Association (ADA) criteria for abnormal glucose tolerance were used. DESIGN, COHORT STUDY, AND RESULTS The ADA HbA1c high-risk cut-off of 39 mmol/mol yielded sensitivity of 45% (95% CI 32, 59), specificity of 84% (95% CI 78, 88), negative predictive value (NPV) of 87% (95% CI 82, 91) and positive predictive value (PPV) of 39% (95% CI 27, 52) for detecting abnormal glucose tolerance. ADA high-risk criterion for FPG of 5.6 mmol/l showed sensitivity of 80% (95% CI 66, 89), specificity of 100% (95% CI 98, 100), NPV of 96% (95% CI 92, 98) and PPV of 100% (95% CI 91, 100). Combining HbA1c ≥39 mmol/mol with FPG ≥5.6 mmol/l yielded sensitivity of 90% (95% CI 78, 96), specificity of 84% (95% CI 78, 88), NPV of 97% (95% CI 94, 99) and PPV of 56% (95% CI 45, 66). CONCLUSIONS Combining test cut-offs of 5.6 mmol/l and HbA1c 39 mmol/mol identifies 90% of women with abnormal glucose tolerance post-GDM (mean 2.6 years (s.d.1.0) post-index pregnancy). Applying this follow-up strategy will reduce the number of OGTT tests required by 70%, will be more convenient for women and their practitioners, and is likely to lead to increased uptake of long-term retesting by these women whose risk for type 2 diabetes is substantially increased.


European Journal of Endocrinology | 2016

Abnormal glucose tolerance post-gestational diabetes mellitus as defined by the International Association of Diabetes and Pregnancy Study Groups criteria

Eoin Noctor; Catherine Crowe; Louise Carmody; Jean Saunders; Breda Kirwan; Angela O'Dea; Paddy Gillespie; Liam G Glynn; Brian E. McGuire; Ciaran O'Neill; Paula O'Shea; Fidelma Dunne

OBJECTIVE An increase in gestational diabetes mellitus (GDM) prevalence has been demonstrated across many countries with adoption of the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) diagnostic criteria. Here, we determine the cumulative incidence of abnormal glucose tolerance among women with previous GDM, and identify clinical risk factors predicting this. DESIGN Two hundred and seventy women with previous IADPSG-defined GDM were prospectively followed up for 5years (mean 2.6) post-index pregnancy, and compared with 388 women with normal glucose tolerance (NGT) in pregnancy. METHODS Cumulative incidence of abnormal glucose tolerance (using American Diabetes Association criteria for impaired fasting glucose, impaired glucose tolerance and diabetes) was determined using the Kaplan-Meier method of survival analysis. Cox regression models were constructed to test for factors predicting abnormal glucose tolerance. RESULTS Twenty-six percent of women with previous GDM had abnormal glucose tolerance vs 4% with NGT, with the log-rank test demonstrating significantly different survival curves (P<0.001). Women meeting IADPSG, but not the World Health Organization (WHO) 1999 criteria, had a lower cumulative incidence than women meeting both sets of criteria, both in the early post-partum period (4.2% vs 21.7%, P<0.001) and at longer-term follow-up (13.7% vs 32.6%, P<0.001). Predictive factors were glucose levels on the pregnancy oral glucose tolerance test, family history of diabetes, gestational week at testing, and BMI at follow-up. CONCLUSIONS The proportion of women developing abnormal glucose tolerance remains high among those with IADPSG-defined GDM. This demonstrates the need for continued close follow-up, although the optimal frequency and method needs further study.


BMC Proceedings | 2012

The prevalence of metabolic syndrome up to 5 years post-partum in patients with a history of gestational diabetes mellitus

Catherine Crowe; Eoin Noctor; Louise Carmody; B Wickham; G Avalos; Geraldine Gaffney; Paula O’Shea; Fidelma Dunne

Metabolic syndrome (MetS) is associated with cardiovascular mortality and increased risk of type 2 diabetes.


BMC Proceedings | 2012

ATLANTIC DIP: The prevalence of pre-diabetes/type 2 diabetes in an Irish population with gestational diabetes mellitus 1-5 years post index pregnancy

Catherine Crowe; Eoin Noctor; Louise Carmody; B Wickham; G Avalos; Geraldine Gaffney; Paula O’Shea; Fidelma Dunne

The ATLANTIC-DIP (diabetes in pregnancy) programme showed 18% of women with gestational diabetes mellitus (GDM) screened with a 75g oral glucose tolerance test (OGTT) 12 weeks post-partum demonstrated glucose intolerance. However, long-term data on progression to type 2 diabetes (T2DM) post gestational diabetes (GDM) in an Irish population is lacking.


BMC Proceedings | 2012

Validation of a diabetes risk score in identifying patients at risk of progression to abnormal glucose tolerance post partum

Catherine Crowe; Eoin Noctor; Louise Carmody; B Wickham; G Avalos; Geraldine Gaffney; Paula O’Shea; Fidelma Dunne

FINDRISC (Finnish Diabetes Risk Score) is a risk assessment tool widely used for the prediction of the development of type 2 diabetes (T2DM), combining a questionnaire with simple anthropometric measurements to identify patients at risk of developing diabetes, with increasing score (0-26) signifying increased risk. A cut off score of 9 has previously been proposed (with drug-treated DM as the endpoint) with a positive predictive value (PPV) of 0.12 and negative predictive value (NPV) of 0.99, area under receiver operating characteristic curve (AuROC)=0.80. It has been well validated in the general population.


Acta Diabetologica | 2015

ATLANTIC-DIP: prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by International Association of Diabetes in Pregnancy Study Groups criteria

Eoin Noctor; Catherine Crowe; Louise Carmody; Breda Kirwan; Angela O’Dea; Liam G Glynn; Brian E. McGuire; Paula O’Shea; Fidelma Dunne


BMC Endocrine Disorders | 2015

Effects of an eight-week supervised, structured lifestyle modification programme on anthropometric, metabolic and cardiovascular risk factors in severely obese adults

Catherine Crowe; Irene Gibson; Katie Cunningham; Claire Kerins; Caroline Costello; Jane Windle; Paula O’Shea; Mary Hynes; Brian E. McGuire; Katriona Kilkelly; Helena Griffin; Tim O′Brien; Jenni Jones; Francis M. Finucane


17th European Congress of Endocrinology | 2015

Skin tags and metabolic phenotype in severely obese adults: the STAMP cohort study

Catherine Crowe; Irene Gibson; Helena Griffin; Anette Murphy; Francis M. Finucane


17th European Congress of Endocrinology | 2015

Effects of an 8-week supervised, structured lifestyle modification programme on anthropometric, metabolic, and cardiovascular risk factors in severely obese adults

Catherine Crowe; Irene Gibson; Katie Cunningham; Claire Kerins; Caroline Costello; Jane Windle; Mary Hynes; Brian E. McGuire; Katriona Kilkelly; Helena Griffin; Jenni Jones; Francis M. Finucane


Irish Journal of Medical Science | 2011

The prevalenace of metabolic syndrome 5 years post partum in patients with a history of GDM

Eoin Noctor; Catherine Crowe; Louise Carmody; B Wickham; G Avalos; Geraldine Gaffney; Paula O'Shea; Fidelma Dunne

Collaboration


Dive into the Catherine Crowe's collaboration.

Top Co-Authors

Avatar

Fidelma Dunne

National University of Ireland

View shared research outputs
Top Co-Authors

Avatar

Louise Carmody

National University of Ireland

View shared research outputs
Top Co-Authors

Avatar

Eoin Noctor

National University of Ireland

View shared research outputs
Top Co-Authors

Avatar

Brian E. McGuire

National University of Ireland

View shared research outputs
Top Co-Authors

Avatar

Paula O’Shea

National University of Ireland

View shared research outputs
Top Co-Authors

Avatar

B Wickham

National University of Ireland

View shared research outputs
Top Co-Authors

Avatar

G Avalos

National University of Ireland

View shared research outputs
Top Co-Authors

Avatar

Geraldine Gaffney

University Hospital Galway

View shared research outputs
Top Co-Authors

Avatar

Breda Kirwan

National University of Ireland

View shared research outputs
Top Co-Authors

Avatar

Francis M. Finucane

National University of Ireland

View shared research outputs
Researchain Logo
Decentralizing Knowledge